Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? (Q44493806)

3 December 2017

title

Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? (English)

1 reference

3 December 2017

1 reference

1 reference

ChEBI release 2020-05-28

10

Axel Haverich

1 reference

3 December 2017

5

Stefan Fischer

1 reference

3 December 2017

Rainer G Leyh

1

1 reference

3 December 2017

Theo Kofidis

2

1 reference

3 December 2017

Theo Kofidis

3

1 reference

3 December 2017

Martin Strüber

4

1 reference

3 December 2017

Karsten Knobloch

6

1 reference

3 December 2017

Bjoern Wachsmann

7

1 reference

3 December 2017

Christian Hagl

8

1 reference

3 December 2017

Andre R Simon

9

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

The Journal of Thoracic and Cardiovascular Surgery

3 December 2017

published in

1 reference

3 December 2017

volume

125

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

1426-1431

1 reference

Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Interleukin-1, interleukin-6 and myocardial enzyme response after coronary artery bypass grafting - a prospective randomized comparison of the conventional and three minimally invasive surgical techniques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Systemic inflammatory response syndrome after cardiac operations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Prevention of the hypoxic reoxygenation injury with the use of a leukocyte-depleting filter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Use of intravenous methylene blue for the treatment of refractory hypotension after cardiopulmonary bypass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Methylene blue administration in septic shock: a clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Methylene blue--a promising treatment modality in sepsis induced by bowel perforation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Pressor and vasoconstrictor effects of methylene blue in endotoxaemic rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Production of nitric oxide during surgery involving cardiopulmonary bypass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

NO., CO and .OH. Endogenous soluble guanylyl cyclase-activating factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2802%2973284-4

10.1016/S0022-5223(02)73284-4

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference